Afatinib Plus Nimotuzumb for NSCLC

Alflutinib Mesylate Versus Gefitinib in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer （FLAG）

NCT03787992 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE3

Afatinib Plus Chemotherapy Against Esophageal or Lung Squamous Cell Carcinoma

NCT03486509 ·Status: UNKNOWN ·Phase: PHASE2

Phase I Study of the Combination of Afatinib and Ruxolitinib in Patients With Treatment-refractory Non-Small Cell Lung Cancer (NSCLC)

NCT02145637 ·Status: COMPLETED ·Phase: PHASE1

To Evaluate the Efficacy of Afatinib in Advanced Lung Squamous Cell Carcinoma With EGFR Sensitive Mutation

NCT04132102 ·Status: UNKNOWN ·Phase: PHASE4

S1403, Afatinib Dimaleate With or Without Cetuximab in Treating Patients With Newly Diagnosed Stage IV or Recurrent, EGFR Mutation Positive Non-small Cell Lung Cancer

NCT02438722 ·Status: COMPLETED ·Phase: PHASE2/PHASE3

Study of EGFR TKI in Patients With Advanced NSCLC Harbouring EGFR Mutations

NCT06062823 ·Status: RECRUITING ·Phase: PHASE2

EGFR-mutated Lung Cancer in Randomized Investigator-Initiated Study

NCT06486142 ·Status: RECRUITING ·Phase: PHASE3

Real-World Effectiveness of Afatinib (Gilotrif) Following Immunotherapy in the Treatment of Metastatic, Squamous Cell Carcinoma of the Lung: A Multi-Site Retrospective Chart Review Study in the U.S.

NCT04750824 ·Status: COMPLETED

A Study of Apatinib Plus EGFR-TKI as First Line Treatment in Patients With Non-squamous NSCLC Harboring EGFR Mutations

NCT03634059 ·Status: UNKNOWN ·Phase: NA

Gefitinib With or Without Simvastatin in Non-Small Cell Lung Cancer (NSCLC)

NCT00452244 ·Status: COMPLETED ·Phase: PHASE2

The Study Observes Afatinib as First-line Treatment in Patients With Epidermal Growth Factor Receptor (EGFR) Mutation-positive Advanced Non-small Cell Lung Cancer

NCT04206787 ·Status: COMPLETED

Firmonertinib 160 mg in Patients With EGFR-Mutant Advanced NSCLC Demonstrating SD After 8 Week Induction With Firmonertinib 80 mg

NCT07298148 ·Status: NOT_YET_RECRUITING ·Phase: PHASE2

A Study of Intermittent, High-dose Afatinib to Determine the Maximal Tolerated Dose and Assess Activity of This Dose Against Non-small Cell Lung Cancer With T790M Mutations

NCT01647711 ·Status: COMPLETED ·Phase: PHASE1

Afatinib and Necitumumab in Patients With EGFR Mutation Positive Advanced or Metastatic Non-small Cell Lung Cancer

NCT03054038 ·Status: TERMINATED ·Phase: PHASE1

Afatinib in NSCLC With HER2 Mutation

NCT02597946 ·Status: COMPLETED ·Phase: PHASE2

To Evaluate the Efficacy of Afatinib in the Treatment of Locally Advanced/Metastatic Non-Small Cell Lung Cancer With NRG1 Fusion

NCT04814056 ·Status: UNKNOWN ·Phase: PHASE4

A Window of Opportunity Trial of Afatinib In Early Stage Non-Small Cell Lung Cancer (NSCLC)

NCT01480141 ·Status: WITHDRAWN ·Phase: PHASE2

Afatinib Combined With Chemotherapy as Conversion Therapy in Unresectable EGFR Sensitive Mutation-positive Stage III NSCLC

NCT06709859 ·Status: RECRUITING ·Phase: PHASE2

Afatinib Treatment for Patients With EGFR Mutation Positive NSCLC Who Are Age 70 or Older

NCT02514174 ·Status: COMPLETED ·Phase: PHASE4

Phase II Study of Gefitinib Plus Nimotuzumab Versus Gefitinib in Non-small Cell Lung Cancer

NCT01498562 ·Status: COMPLETED ·Phase: PHASE2

Afatinib in Lung Cancer With EGFR Mutation From Circulating Tumor DNA

NCT02629523 ·Status: COMPLETED ·Phase: PHASE2

Neoadjuvant Afatinib Therapy for Potentially Resectable Stage III EGFR Mutation-Positive Lung Adenocarcinoma

NCT04201756 ·Status: COMPLETED ·Phase: PHASE2

The Continuation of Gefitinib Treatment Beyond Progression in Non-small Cell Lung Cancer Patients With EGFR Mutation

NCT03399669 ·Status: UNKNOWN ·Phase: PHASE2

Afatinib in EGFR+NSCLC (Recurrent or Stage IV) - Patients With Poor Performance Status (ECOG 2 or 3)

NCT02695290 ·Status: TERMINATED ·Phase: PHASE4

Retrospective Multi-cohort Study of Frontline Afatinib Followed by 2nd Line Therapy Including Osimertinib, Chemotherapy or Other Therapy

NCT04930133 ·Status: UNKNOWN